Regular Hours
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| Valuation Estimation |
|
EPS (Current/Estimated)
1.28/0.19
|
|
Enterprise Value
794.27M
|
| Balance Sheet |
|
Book Value Per Share
6.05
|
| Cash Flow |
|
Cash Flow Yield
0.05
|
| Income Statement |
|
Total Revenue
333.79M
|
|
Operating Revenue Per Share
5.78
|
|
Industry Comparison
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
Quotes are at least 15-min delayed:2025/11/08 13:49 EST
Industry overview quotes are at least 15 minutes delayed
|
Business Description
|
|||
| CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services. |

15.62 
